# DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer

Source: https://onco.cc/key-papers/paper-duo-e-jco-2023/  
OnCo record `paper-duo-e-jco-2023` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Adding durvalumab to first-line chemotherapy delayed progression in advanced endometrial cancer, and adding the PARP inhibitor olaparib to durvalumab maintenance helped further in mismatch repair-proficient tumours.

## Summary

Phase 3 trial of 718 patients with newly diagnosed advanced or recurrent endometrial cancer randomised to carboplatin-paclitaxel alone, with durvalumab followed by durvalumab maintenance, or with durvalumab followed by durvalumab plus olaparib maintenance.

Progression-free survival hazard ratios were 0.71 for durvalumab and 0.55 for durvalumab plus olaparib versus control; in mismatch repair-deficient disease both immunotherapy arms performed similarly (hazard ratio about 0.42), whereas olaparib added benefit in proficient disease (0.57 versus 0.77).

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: Journal of Clinical Oncology
- Year: 2024
- DOI: 10.1200/JCO.23.02132
- Authors: Westin SN, Moore K, Chon HS, et al.
- Findings: Progression-free survival hazard ratio 0.71 (durvalumab) and 0.55 (durvalumab plus olaparib).; Mismatch repair-proficient: hazard ratio 0.77 vs 0.57 with olaparib added.
- What it means: Durvalumab-based chemo-immunotherapy is a third first-line option with RUBY and NRG-GY018, and durvalumab plus olaparib maintenance is approved for mismatch repair-proficient disease in some regions.
- Caveats: The contribution of olaparib in proficient disease may be concentrated in p53-abnormal tumours; overall survival immature.; Anaemia and neutropenia increased with olaparib.

## Sources

- J Clin Oncol 2024: https://doi.org/10.1200/JCO.23.02132
- PubMed: https://pubmed.ncbi.nlm.nih.gov/37864337/

## Connected records

- cancers: [Advanced or recurrent endometrial cancer](https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Olaparib](https://onco.cc/drugs/olaparib/)
- trials: [DUO-E / GOG-3041 / ENGOT-EN10](https://onco.cc/trials/duo-e/)
- journals: [Journal of Clinical Oncology](https://onco.cc/journals/jco/)

---
JSON: https://onco.cc/api/v1/entities/paper-duo-e-jco-2023.json